ORYZON presents positive efficacy results on iadademstat in ED-SCLC patients at ESMO-2019
MADRID, SPAIN and CAMBRIDGE MA.
• 75% of responses in the first 8 evaluable patients treated with the triple combination of iadademstat plus carboplatin-etoposide
• Main toxicity of the combination is hematological
• Iadademstat alone is safe, does not produce hematological or neurological toxicity and shows clinical benefit, suggesting potential for monotherapy
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announces additional data from CLEPSIDRA, an ongoing Phase II trial investigating iadademstat in combination with standard of-care in relapsed extensive disease (ED) small cell lung cancer (SCLC) patients. The data were presented on Saturday, September 28 at the ongoing ESMO Congress 2019 in Barcelona, Spain.